Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: Glucose Monitoring, Other Jun 16 | 2022Senseonics Eversense E3 CGM Receives CE Mark; Tandem Appoints Two New Members to Board of Directors; Akero Announces Financing Transactions with Pfizer and Hercules CapitalPurchase Blast
$599
Posted in: Glucose Monitoring Jun 14 | 2022Updated Abbott vs. Dexcom CGM Tale-of-the-tape AnalysisPurchase Blast
$599
Posted in: GLP-1RA, Other Jun 09 | 2022Zealand Presents Ph1 Dapiglutide Trial Data; Novo and GluCare Partnership for Innovative Weight Management Program; Ginkgo and Novo Collaboration on Expression Systems; Sanofi launches first Digital AcceleratorPurchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Glucose Monitoring, Insulin Delivery, Other Jun 08 | 2022Thoughts after ATTD and ADA 2022Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other Jun 07 | 2022Lilly ADA 2022 Investor CallPurchase Blast
$599
Posted in: DPP-IVi, Glucose Monitoring, Insulin Delivery, Other, SGLT2i Jun 06 | 2022ADA 2022 Key Press Releases (June 5-6)Purchase Blast
$599
Posted in: GLP-1RA, GLP-1RA + Basal, Other Jun 06 | 2022Novo Hosts ADA 2022 Investor EventPurchase Blast$599
Posted in: Dual/triple agonist, GLP-1RA, Insulin Delivery, Other Jun 04 | 2022ADA 2022 Key Press Releases (June 4)Purchase Blast$599
Posted in: Basal Insulin, Glucose Monitoring, Other Jun 03 | 2022ADA 2022 Key Press Releases (June 3)Purchase Blast
$599
Posted in: Basal Insulin, Other Jun 01 | 2022First Cagrisema Pivotal Trial on CT.gov; Lannett Doses 50% of Patients in Bs-glargine Pivotal TrialPurchase Blast
$599
Posted in: Glucose Monitoring, Other, SGLT2i May 31 | 2022Abbott Announces Libre 3 Clearance; Lexicon Resubmits Sota NDA; Dexcom Denies Insulet Acquisition SpeculationPurchase Blast
$599
Posted in: Glucose Monitoring, Other May 26 | 2022Bigfoot Hires Matt Rainville as CCO; Medtronic CY Q1 ’22 (FY Q4 ’22) Earnings Update; Pfizer’s NASH Combo Receives Fast Track Designation; ReShape and OpenLoop Collaboration for Virtual Weight Loss Coaching ProgramPurchase Blast
$599
Posted in: GLP-1RA + Basal, Other May 25 | 2022Bayer Presents New Finerenone Analysis; Lilly to Invest $2.1B in Additional Manufacturing Capacity; Oramed Granted Combination Therapy Patent for Oral GLP-1+InsulinPurchase Blast$599
Posted in: Dual/triple agonist, GLP-1RA, Other May 24 | 2022Mounjaro WAC Pricing Analysis; Lilly @ UBS 2022Purchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Glucose Monitoring, Other May 19 | 2022Provention Hosts Teplizumab Commercial Launch Investor Event; Lifescan Initiates New RWE Study; Diamyd Enrolls First Patient in Ph3 T1DM Vaccine Trial; Dario Announces New Employer and Provider Contracts; MySugarWatch Expands DTC Marketing Campaign; Adocia Q1 ’22 Earnings UpdatePurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other May 18 | 2022Mounjaro (tirzepatide) Label and Website AnalysisPurchase Blast
$599
Posted in: GLP-1RA, Insulin Delivery, Other, SGLT2i May 17 | 2022MannKind to Acquire Zealand’s V-Go T2DM Patch Pump; Sernova/Evotec Collaboration for Beta Cell Therapy; AACE Updates NAFLD GuidelinesPurchase Blast
$599
Posted in: Other May 16 | 2022May 16-19 CHMP Agenda; Glyscend Therapeutics Completes Ph1 GLY-200 Trial in T2DMPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, Other May 16 | 2022Movano and Embecta Q1 ’22 Earnings Updates; Hygieia Launches d-Nav Clinical Partnership Program in MichiganPurchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
